Navigation Links
Cell Therapeutics, Inc. Sells $64.5 million Units Consisting of Preferred Stock, New 2014 Convertible Senior Notes and Warrants to a Single Institutional Investor
Date:4/30/2008

price), for an aggregate potential exercise price of $27.1 million. The investor will also receive a second warrant which entitles it to purchase $67.5 million of additional notes and warrants. The Company will have the ability to accelerate the termination date of the warrant in the event that the Company meets one of two potential milestone events as well as other conditions to be more fully described in the Company's Form 8-K for this transaction.

Up to $5,250,000 in principal amount of existing 9% Convertible Senior Notes due 2012, along with all warrants issued in connection with such notes, may be exchanged for an equal amount in principal of new securities in the offering.

The Company intends to use the net proceeds from this offering to retire the remaining balance of the 2008 Senior and Junior Convertible Notes due June 15, 2008 of approximately $10.8 million, to acquire access to Bayer-Schering's phase III "FIT" trial data to submit an sBLA application for label expansion of Zevalin in the US and for general working capital.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ: RODM), acted as the exclusive placement agent for the offering.

A prospectus supplement relating to the Preferred Stock and Convertible Notes to be issued in the offering will be filed with Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained directly from Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in whi
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
2. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
3. Cell Therapeutics, Inc. Announces Receipt of Letter From the NASDAQ Stock Market Regarding Non-Compliance With the Minimum Bid Price Requirement
4. Cell Therapeutics, Inc. Announces Filing of Form 10-K
5. Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award
6. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
7. Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities
8. Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
9. Cell Therapeutics, Inc. (CTI) to Present at 7th Annual WBBA Invest Northwest Conference
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 13
11. Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... 2015  Adaptive Biotechnologies today announced the recent ... The University of Texas MD Anderson Cancer Center ... identification and quantification of populations of B cells ... of people with classical Hodgkin,s lymphoma (CHL). The ... Haematology , represent a first step toward developing ...
(Date:4/28/2015)... ANN ARBOR, Mich. , April 28, 2015 ... OncoTargets and Therapy today shows that the Paradigm ... FoundationOne test across a number of key clinical variables, ... The purpose of the analysis was to ... for profiling cancer patients compared with each other.  ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 More than ... psychosis at some point over the course of their ... symptoms that worsen as the disease progresses. ReachMD ... announces the launch of a series dedicated to PD ... in PD, movement disorders, and psychiatric conditions. , The ...
(Date:4/28/2015)... York, New York (PRWEB) April 28, 2015 ... operations including sales, marketing, and customer service operations across ... The Eeva Test , the first and only FDA-cleared ... proprietary algorithm to aid in embryo selection during IVF. ... career in the field of Reproductive Sciences, including both ...
Breaking Biology Technology:Adaptive Biotechnologies and Researchers from MD Anderson Cancer Center Demonstrate Ability to Detect Hodgkin's Lymphoma in Blood 2Adaptive Biotechnologies and Researchers from MD Anderson Cancer Center Demonstrate Ability to Detect Hodgkin's Lymphoma in Blood 3Paradigm Cancer Diagnostic Test (PCDx) Performed Better Than FoundationOne In Side by Side Clinical Study 2Paradigm Cancer Diagnostic Test (PCDx) Performed Better Than FoundationOne In Side by Side Clinical Study 3ReachMD Launches Series Focusing on Parkinson’s Disease Psychosis 2Progyny Appoints Gary Harton as Group Senior Vice President, Commercial Development 2
... Continues to ... Broaden Product Portfolio, WAYNE, Pa., Feb. 14 ... fiscal second quarter and,six months ended December 31, 2007., For ... the Company,s Drew, Vascular and Escalon Digital Solutions (EMI),business units, which ...
... PALO ALTO, Calif., Feb. 14 CV Therapeutics,Inc. ... accordance with Nasdaq,marketplace rule 4350, the Company issued ... due to additional hiring, primarily in,connection with its ... inducement stock options cover an aggregate 119,200 shares ...
... WASHINGTON, Feb. 14 As part of ... create a pathway for,FDA approval of safe and ... features a footprint in the snow stating: "Don,t ... highlights how meaningful biogenerics legislation should be,balanced to ...
Cached Biology Technology:Escalon(R) Reports Second Quarter Fiscal 2008 Results 2Escalon(R) Reports Second Quarter Fiscal 2008 Results 3Escalon(R) Reports Second Quarter Fiscal 2008 Results 4Escalon(R) Reports Second Quarter Fiscal 2008 Results 5Escalon(R) Reports Second Quarter Fiscal 2008 Results 6Escalon(R) Reports Second Quarter Fiscal 2008 Results 7Escalon(R) Reports Second Quarter Fiscal 2008 Results 8CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 2
(Date:3/31/2015)... 2015   Guidepoint , a leading global research ... Pain Management TRACKER, part of the Guidepoint TRACKER ... the medical device and therapeutics markets. The Post-Surgical Pain ... volumes, market share, and adoption rates across three major ... surgery. The Post-Surgical Pain Management TRACKER will ...
(Date:3/26/2015)... , March 26, 2015 ... family, social, recreation and athletic club, today announced it ... to allow freedom of movement for members and staff, ... "Following a comprehensive process, we selected FST,s IMID Access ... and convenience for our members and staff, in addition ...
(Date:3/24/2015)... ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition of the ... report to their offering. This report analyzes the worldwide ... following Segments: Face Biometrics, and Voice Biometrics. The report provides separate ... Japan , Europe , ... Africa , and Latin America . ...
Breaking Biology News(10 mins):Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
... by a particular enzyme to modify bacterial chromosome chemistry, ... new kind of drug that could stop virulent bacterial ... in the May 6 issue of the journal Cell. ... enzyme called Dam (DNA adenine methyltransferase) plays a role ...
... that can survive encounters with specific immune system cells ... cells, known as neutrophils, dictate whether our immune system ... the research was released today online in The Journal ... Laboratories (RML), part of the National Institute of Allergy ...
... the field of human embryonic stem cell research receives ... also exploring the potential of adult stem cells for ... adult stem cell research isn't fraught with the controversies ... extremely difficult to isolate and then to multiply in ...
Cached Biology News:Scientists take aim at virulent bacteria by decoding machinery of key control enzyme 2Scientists reveal how disease bacterium survives inside immune system cell 2Scientists reveal how disease bacterium survives inside immune system cell 3Researchers discover mechanism for multiplying adult stem cells 2
Request Info...
Secure-Seal™ spacer, one well, 20 mm diameter, 0.12 mm deep *set of 100*...
Synphilin 1 Immunogen: Synthetic peptide corresponding to residues S(829) L E L N G E K D K D K G R T L Q R T(847) of human Synphilin 1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Request Info...
Biology Products: